Jan 31 (Reuters) - The European Commission has requested

its medicines regulator to consider safety information on Eisai ( ESALF )

and Biogen's Alzheimer's drug Leqembi, the

agency said on Friday.

The safety information to be reviewed was made available

after November, when the regulator had recommended approval of

the drug for some patients with early Alzheimer's disease.

(Reporting by Bhanvi Satija in Bengaluru; Editing by Shinjini

Ganguli)